AVITA Medical (RCEL) Stock Forecast, Price Target & Predictions
RCEL Stock Forecast
AVITA Medical stock forecast is as follows: an average price target of $9.00 (represents a -12.28% downside from RCEL’s last price of $10.26) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RCEL Price Target
The average price target for AVITA Medical (RCEL) is $9.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential -12.28% downside from RCEL's last price of $10.26.
RCEL Analyst Ratings
According to 5 Wall Street analysts, AVITA Medical's rating consensus is 'Buy'. The analyst rating breakdown for RCEL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AVITA Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Matt O'Brien | Piper Sandler | $9.00 | $8.35 | 7.78% | -12.28% |
The latest AVITA Medical stock forecast, released on May 14, 2024 by Matt O'Brien from Piper Sandler, set a price target of $9.00, which represents a 7.78% increase from the stock price at the time of the forecast ($8.35), and a -12.28% decrease from RCEL last price ($10.26).
AVITA Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.00 |
| Last Closing Price | $10.26 | $10.26 | $10.26 |
| Upside/Downside | -100.00% | -100.00% | -12.28% |
In the current month, the average price target of AVITA Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AVITA Medical's last price of $10.26. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 14, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 14, 2024 | Piper Sandler | - | Neutral | Downgrade |
| Jun 27, 2023 | Cantor Fitzgerald | - | Overweight | Initialise |
| Jun 16, 2021 | BTIG | Buy | Buy | Hold |
AVITA Medical's last stock rating was published by Cowen & Co. on Aug 09, 2024. The company gave RCEL a "Buy" rating, the same as its previous rate.
AVITA Medical Financial Forecast
AVITA Medical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.64M | $11.75M | $10.55M | $9.46M | $9.09M | $8.34M | $7.54M | $6.94M | $7.02M | $10.30M | $8.77M | $5.10M | $5.06M | $3.88M |
| Avg Forecast | $32.60M | $28.50M | $24.75M | $20.60M | $23.22M | $19.44M | $14.52M | $11.08M | $14.20M | $13.40M | $11.30M | $10.28M | $8.80M | $7.48M | $7.32M | $7.24M | $8.28M | $7.33M | $4.94M | $5.10M | $3.88M | $7.97M | $3.61M |
| High Forecast | $33.24M | $29.06M | $25.23M | $21.00M | $23.67M | $19.82M | $14.80M | $11.30M | $15.89M | $13.66M | $11.52M | $10.48M | $8.97M | $7.63M | $7.32M | $7.61M | $8.70M | $7.70M | $5.19M | $5.36M | $4.08M | $8.38M | $3.80M |
| Low Forecast | $31.89M | $27.88M | $24.21M | $20.15M | $22.72M | $19.02M | $14.20M | $10.84M | $13.36M | $13.11M | $11.06M | $10.06M | $8.61M | $7.32M | $7.32M | $6.86M | $7.84M | $6.94M | $4.68M | $4.83M | $3.67M | $7.55M | $3.42M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.04% | 1.03% | 1.07% | 1.21% | 1.14% | 1.04% | 0.84% | 0.96% | 2.09% | 1.72% | 1.32% | 0.64% | 1.07% |
AVITA Medical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $14.20M, with a low forecast of $13.36M, and a high forecast of $15.89M. RCEL's average Quarter revenue forecast represents a 4.03% increase compared to the company's last Quarter revenue of $13.64M (Sep 23).
AVITA Medical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-8.53M | $8.31M | $-9.05M | $-5.19M | $-5.44M | $-6.12M | $-9.46M | $-8.45M | $-5.76M | $-4.53M | $-5.82M | $-5.46M | $-10.00M | $-12.90M |
| Avg Forecast | $-31.18M | $-27.26M | $-23.67M | $-19.70M | $-22.21M | $-18.59M | $-13.89M | $-11.82M | $-13.58M | $-12.82M | $-10.81M | $-12.22M | $-8.42M | $-13.40M | $-7.00M | $-11.69M | $-7.87M | $-10.88M | $-7.64M | $-8.66M | $-9.94M | $-292.02M | $-10.24M |
| High Forecast | $-30.51M | $-26.67M | $-23.16M | $-19.28M | $-21.73M | $-18.19M | $-13.59M | $-9.46M | $-12.78M | $-12.54M | $-10.57M | $-9.78M | $-8.24M | $-10.72M | $-7.00M | $-9.35M | $-7.46M | $-8.71M | $-6.11M | $-6.92M | $-7.95M | $-233.62M | $-8.19M |
| Low Forecast | $-31.79M | $-27.79M | $-24.14M | $-20.09M | $-22.64M | $-18.96M | $-14.16M | $-14.18M | $-15.20M | $-13.07M | $-11.02M | $-14.66M | $-8.58M | $-16.08M | $-7.00M | $-14.03M | $-8.28M | $-13.06M | $-9.16M | $-10.39M | $-11.93M | $-350.43M | $-12.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.67% | -0.77% | 0.74% | 0.62% | 0.41% | 0.87% | 0.81% | 1.07% | 0.53% | 0.59% | 0.67% | 0.55% | 0.03% | 1.26% |
4 analysts predict RCEL's average Quarter EBITDA for Sep 23 to be $-12.82M, with a high of $-12.54M and a low of $-13.07M. This is -254.22% lower than AVITA Medical's previous annual EBITDA (Jun 23) of $8.31M.
AVITA Medical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-8.71M | $-10.38M | $-9.22M | $-5.35M | $-5.59M | $-6.26M | $-9.46M | $-8.48M | $-5.95M | $-4.72M | $-6.00M | $-5.64M | $-10.23M | $-12.91M |
| Avg Forecast | $-3.19M | $-8.13M | $-14.30M | $-22.81M | $-12.29M | $-16.54M | $-18.32M | $-12.03M | $-14.12M | $-17.27M | $-11.97M | $-12.44M | $-9.00M | $-13.84M | $-12.67M | $-11.90M | $-10.23M | $-11.24M | $-7.96M | $-8.92M | $-10.26M | $-298.68M | $-10.25M |
| High Forecast | $-3.10M | $-7.90M | $-13.90M | $-22.17M | $-11.95M | $-13.78M | $-17.80M | $-9.63M | $-13.72M | $-16.79M | $-11.64M | $-9.95M | $-8.75M | $-11.07M | $-12.67M | $-9.52M | $-9.53M | $-8.99M | $-6.37M | $-7.14M | $-8.21M | $-238.94M | $-8.20M |
| Low Forecast | $-3.27M | $-8.33M | $-14.67M | $-23.39M | $-12.60M | $-18.90M | $-18.78M | $-14.44M | $-14.48M | $-17.71M | $-12.28M | $-14.93M | $-9.23M | $-16.60M | $-12.67M | $-14.28M | $-10.92M | $-13.49M | $-9.55M | $-10.71M | $-12.31M | $-358.42M | $-12.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.74% | 0.59% | 0.40% | 0.49% | 0.80% | 0.83% | 0.53% | 0.59% | 0.67% | 0.55% | 0.03% | 1.26% |
AVITA Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCEL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AVITA Medical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $16.66M | $-3.84M | $14.84M | $11.66M | $10.41M | $10.80M | $12.36M | $10.60M | $8.87M | $9.42M | $9.07M | $7.00M | $11.74M | $14.67M |
| Avg Forecast | $240.41M | $210.18M | $182.52M | $151.92M | $171.24M | $143.36M | $107.05M | $81.71M | $104.68M | $98.82M | $83.33M | $75.81M | $64.90M | $55.19M | $53.96M | $50.20M | $57.38M | $50.79M | $34.24M | $35.36M | $26.90M | $55.26M | $25.04M |
| High Forecast | $245.12M | $214.29M | $186.09M | $154.89M | $174.59M | $146.17M | $109.15M | $83.31M | $117.19M | $100.75M | $84.96M | $77.29M | $66.17M | $56.27M | $53.96M | $52.79M | $60.34M | $53.41M | $36.00M | $37.19M | $28.29M | $58.11M | $26.33M |
| Low Forecast | $235.21M | $205.63M | $178.57M | $148.63M | $167.53M | $140.26M | $104.74M | $79.94M | $98.50M | $96.68M | $81.53M | $74.17M | $63.49M | $53.99M | $53.96M | $47.54M | $54.34M | $48.10M | $32.42M | $33.49M | $25.48M | $52.33M | $23.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.17% | -0.05% | 0.20% | 0.18% | 0.19% | 0.20% | 0.25% | 0.18% | 0.17% | 0.28% | 0.26% | 0.26% | 0.21% | 0.59% |
AVITA Medical's average Quarter SG&A projection for Dec 23 is $104.68M, based on 5 Wall Street analysts, with a range of $98.50M to $117.19M. The forecast indicates a 528.50% rise compared to RCEL last annual SG&A of $16.66M (Sep 23).
AVITA Medical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.41 | $-0.37 | $-0.24 | $-0.22 | $-0.25 | $-0.38 | $-0.34 | $-0.24 | $-0.19 | $-0.26 | $-0.26 | $-0.48 | $-0.61 |
| Avg Forecast | $-0.13 | $-0.32 | $-0.56 | $-0.90 | $-0.48 | $-0.65 | $-0.72 | $-0.53 | $-0.56 | $-0.68 | $-0.47 | $-0.40 | $-0.35 | $-0.51 | $-0.50 | $-0.46 | $-0.40 | $-0.48 | $-0.65 | $-0.35 | $-0.21 | $-0.19 | $-0.20 |
| High Forecast | $-0.12 | $-0.31 | $-0.55 | $-0.87 | $-0.47 | $-0.54 | $-0.70 | $-0.52 | $-0.54 | $-0.66 | $-0.46 | $-0.39 | $-0.34 | $-0.50 | $-0.50 | $-0.43 | $-0.38 | $-0.45 | $-0.61 | $-0.33 | $-0.20 | $-0.17 | $-0.19 |
| Low Forecast | $-0.13 | $-0.33 | $-0.58 | $-0.92 | $-0.50 | $-0.74 | $-0.74 | $-0.54 | $-0.57 | $-0.70 | $-0.48 | $-0.41 | $-0.36 | $-0.52 | $-0.50 | $-0.50 | $-0.43 | $-0.52 | $-0.69 | $-0.37 | $-0.23 | $-0.20 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.87% | 0.92% | 0.68% | 0.43% | 0.50% | 0.82% | 0.84% | 0.50% | 0.29% | 0.74% | 1.22% | 2.57% | 3.07% |
According to undefined Wall Street analysts, AVITA Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCEL previous annual EPS of $NaN (undefined).
AVITA Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| TELA | TELA Bio | $2.65 | $14.00 | 428.30% | Buy |
| DCTH | Delcath Systems | $9.54 | $22.00 | 130.61% | Buy |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| VREX | Varex Imaging | $11.82 | $17.00 | 43.82% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| IRMD | IRadimed | $48.47 | $60.00 | 23.79% | Buy |
| TMDX | TransMedics Group | $151.42 | $156.86 | 3.59% | Buy |
| CLPT | ClearPoint Neuro | $12.59 | $12.00 | -4.69% | Buy |
| RCEL | AVITA Medical | $10.26 | $9.00 | -12.28% | Buy |
RCEL Forecast FAQ
Is AVITA Medical a good buy?
Yes, according to 5 Wall Street analysts, AVITA Medical (RCEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RCEL's total ratings.
What is RCEL's price target?
AVITA Medical (RCEL) average price target is $9 with a range of $9 to $9, implying a -12.28% from its last price of $10.26. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AVITA Medical stock go up soon?
According to Wall Street analysts' prediction for RCEL stock, the company can go down by -12.28% (from the last price of $10.26 to the average price target of $9), down by -12.28% based on the highest stock price target, and down by -12.28% based on the lowest stock price target.
Can AVITA Medical stock reach $20?
RCEL's average twelve months analyst stock price target of $9 does not support the claim that AVITA Medical can reach $20 in the near future.
What are AVITA Medical's analysts' financial forecasts?
AVITA Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $68.26M (high $69.59M, low $66.78M), average EBITDA is $-66.51M (high $-62.963M, low $-69.944M), average net income is $-59.174M (high $-53.151M, low $-64.721M), average SG&A $503.36M (high $513.21M, low $492.48M), and average EPS is $-2.387 (high $-2.229, low $-2.524). RCEL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $106.45M (high $108.53M, low $104.15M), average EBITDA is $-102M (high $-99.619M, low $-104M), average net income is $-48.434M (high $-47.072M, low $-49.666M), average SG&A $785.02M (high $800.39M, low $768.05M), and average EPS is $-1.907 (high $-1.853, low $-1.955).
Did the RCEL's actual financial results beat the analysts' financial forecasts?
Based on AVITA Medical's last annual report (Dec 2022), the company's revenue was $34.42M, beating the average analysts forecast of $30.84M by 11.61%. Apple's EBITDA was $-26.045M, missing the average prediction of $-40.506M by -35.70%. The company's net income was $-26.665M, missing the average estimation of $-47.414M by -43.76%. Apple's SG&A was $45.24M, missing the average forecast of $224.24M by -79.82%. Lastly, the company's EPS was $-1.07, missing the average prediction of $-1.829 by -41.50%. In terms of the last quarterly report (Sep 2023), AVITA Medical's revenue was $13.64M, beating the average analysts' forecast of $13.4M by 1.83%. The company's EBITDA was $-8.527M, missing the average prediction of $-12.817M by -33.47%. AVITA Medical's net income was $-8.712M, missing the average estimation of $-17.271M by -49.56%. The company's SG&A was $16.66M, missing the average forecast of $98.82M by -83.15%. Lastly, the company's EPS was $-0.34, missing the average prediction of $-0.68 by -49.99%